Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
Key PointsSubstantial revenue from its flagship drug Casgevy should be right around the corner.
Key PointsSubstantial revenue from its flagship drug Casgevy should be right around the corner.